Sad and infuriating, but highly likely to be dead on. Again, sad and infuriating, there is not one documentable piece of counter evidence in financial reports, or in public domain, at this time. Great product possibilities are totally overwhelmed by nonperformance of CEO et al.
I do give credit to Intent Sciences for having a visible footprint of actually earning their shares in the now-expired one year agreement. Obviously, no large, notable medical publication would cover a company with less than <$500 organic, annual sales, but they did what they could to try to change that.
News 
Market Data 
Discover 
